On Aug. 6, 2020, RedHill Biopharma announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks (COFEPRIS) for the Company’s Clinical Trial Authorization application for the Phase 2/3 study evaluating opaganib (Yeliva, ABC294640)1 in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.